Epiomic Epidemiology Series: Huntington's Disease Forecast in 8 Major Markets 2015-2025

August 2015 | 36 pages | ID: EF363F0508EEN
Black Swan Analysis limited

Abstracts

Huntington’s disease is an inherited autosomal dominant condition and its progression leads to a deteriorative neurological disorder. Middle age is the more frequent age onset of this disease and is linked with duration of survival. This report provides the current prevalent population for Huntington’s disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides a 10-year forecast projection based on population trends in each of the major markets. The report also contains a disease overview including risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Huntington’s patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Huntington’s disease include:

• Total functional capacity by stage
• Nervous system dysfunction
• Psychiatric disorders
• Cognitive disorders
• Major depressive disorder
• Personality changes
• Anxiety disorders
• Nocturia
• Moderate/Severe Sleep disturbance

The report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in the global Huntington’s disease market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of WG and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a greater understanding of the level of impact from specific co-morbid conditions on the Huntington’s disease prevalent population.
• Identify sub-populations within Huntington’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Huntington’s disease patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Unified Huntington’s Disease Rating Scale (UHDRS)
Total Functional Capacity
Methodology
Top-Line Huntington’s Disease Prevalence
Prevalence of UHDRS Components within the Huntington’s Disease Cohort
  Total Functional Capacity Stage Breakdown
  Prevalence of Motor Dysfunction in Huntington’s Patients
  Prevalence of Behavioural Dysfunction in Huntington’s Patients
  Prevalence of Cognitive dysfunction in Huntington’s Patients
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Total functional capacity scores and stages
Prevalence of Huntington’s Disease, total (000s)
Prevalence of Huntington’s Disease, males (000s)
Prevalence of Huntington’s Disease, females (000s)
Huntington’s Disease by TFC stage (000s)
Huntington’s Disease patients with autonomic nervous system dysfunction (000s)
Huntington’s Disease patients with psychiatric disorders (000s)
Huntington’s Disease patients with major depressive disorder (000s)
Huntington’s Disease patients with personality changes (000s)
Huntington’s Disease patients with any anxiety disorder (000s)
Huntington’s Disease patients with cognitive disorders (000s)
Huntington’s Disease patients with nocturia (000s)
Huntington’s Disease patients with moderate o severe sleep disturbance (000s)
USA Prevalence of Huntington’s by 5-yr age cohort, males (000s)
USA Prevalence of Huntington’s by 5-yr age cohort, females (000s)
France Prevalence of Huntington’s by 5-yr age cohort, males (000s)
France Prevalence of Huntington’s by 5-yr age cohort, females (000s)
Germany Prevalence of Huntington’s by 5-yr age cohort, males (000s)
Germany Prevalence of Huntington’s by 5-yr age cohort, females (000s)
Italy Prevalence of Huntington’s by 5-yr age cohort, males (000s)
Italy Prevalence of Huntington’s by 5-yr age cohort, females (000s)
Spain Prevalence of Huntington’s by 5-yr age cohort, males (000s)
Spain Prevalence of Huntington’s by 5-yr age cohort, females (000s)
United Kingdom Prevalence of Huntington’s by 5-yr age cohort, males (000s)
United Kingdom Prevalence of Huntington’s by 5-yr age cohort, females (000s)
Brazil Prevalence of Huntington’s by 5-yr age cohort, males (000s)
Brazil Prevalence of Huntington’s by 5-yr age cohort, females (000s)
Japan Prevalence of Huntington’s by 5-yr age cohort, males (000s)
Japan Prevalence of Huntington’s by 5-yr age cohort, females (000s)